Cargando…

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma

High-dose methotrexate (HD-MTX) at 3 g/m(2) is one of the strategies for central nervous system (CNS) prophylaxis in the first-line treatment of aggressive lymphomas, especially in diffuse large B cell lymphoma patients with high-risk CNS-International Prognostic Index. The objective of our study wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernard, S., Hachon, L., Diasonama, J. F., Madaoui, C., Aguinaga, L., Miekoutima, E., Moatti, H., Perrial, Emeline, Madelaine, I., Brice, P., Thieblemont, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960588/ https://www.ncbi.nlm.nih.gov/pubmed/33608849 http://dx.doi.org/10.1007/s00277-020-04341-7

Ejemplares similares

P1217: INTRATHECAL METHOTREXATE PROPHYLAXIS AND CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH INTENSIFIED R-ACVBP STRATEGY
por: Renaud, L., et al.
Publicado: (2022)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
por: Moatti, Hannah, et al.
Publicado: (2022)

High‐dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma
por: Akiyama, Hiroki, et al.
Publicado: (2016)

Management of aggressive lymphoma in very elderly patients
por: Thieblemont, Catherine, et al.
Publicado: (2017)

The Analysis of Treatment of Aggressive Fibromatosis Using Oral Methotrexate Chemotherapy
por: Yoon, Gi Woon, et al.
Publicado: (2014)

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
por: Fan, Ni, et al.
Publicado: (2017)

Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma
por: Wang, Yi-Xia, et al.
Publicado: (2020)

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
por: Bobillo, Sabela, et al.
Publicado: (2021)

A Proposed Methodology to Deal with the Impact of In Vitro Cellular Matrix on the Analytical Performances of a Targeted Metabolomic LC-HRMS Method
por: Guitton, Jérôme, et al.
Publicado: (2023)

Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration
por: Fráňová, J., et al.
Publicado: (2016)

Evaluation, Identification, and Management of Acute Methotrexate Toxicity in High-dose Methotrexate Administration in Hematologic Malignancies
por: Feinsilber, Doron, et al.
Publicado: (2018)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma
por: Lee, Bryan S., et al.
Publicado: (2014)

Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma
por: Song, Kyung Mee, et al.
Publicado: (2018)

Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma
por: Fujimoto, Kenji, et al.
Publicado: (2020)

Primary Central Nervous System T-cell Lymphoma as Methotrexate-associated Lymphoproliferative Disorders: Case Report
por: KAWANO, Hiroto, et al.
Publicado: (2021)

A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma
por: Villanueva, Gabriela, et al.
Publicado: (2023)

Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
por: Zerbit, Jeremie, et al.
Publicado: (2020)

Formulation and In Vitro Evaluation of Ufasomes for Dermal Administration of Methotrexate
por: Sharma, Arvind, et al.
Publicado: (2012)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma: Erratum
Publicado: (2014)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells
por: Takashima, Yasuo, et al.
Publicado: (2019)

Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates
por: Viricel, Warren, et al.
Publicado: (2019)

Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer
por: Bazan, F., et al.
Publicado: (2019)

Central Nervous System Prophylaxis and Treatment in Acute Leukemias
por: Wu, Susan Y., et al.
Publicado: (2022)

Surgical antibiotic prophylaxis administration practices
por: Shrestha, S., et al.
Publicado: (2021)

Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice
por: Mueller, Andre M., et al.
Publicado: (2013)

Psoriatic flare after the concomitant administration of L-methylfolate and methotrexate
por: Nazarian, Roya S., et al.
Publicado: (2016)

Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice
por: Yousefi, Gholamhossein, et al.
Publicado: (2018)

Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report
por: Shimada, Hiromi, et al.
Publicado: (2015)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft‐versus‐host disease prophylaxis
por: Garming Legert, Karin, et al.
Publicado: (2020)

Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom
por: Roschewski, Mark
Publicado: (2021)

High-Dose Methotrexate for the Treatment of Relapsed Central Nervous System Erdheim-Chester Disease
por: Ho, Prahlad, et al.
Publicado: (2014)

Treatment of Recurrent Posttransplant Lymphoproliferative Disorder of the Central Nervous System with High-Dose Methotrexate
por: Twist, Clare J., et al.
Publicado: (2013)

Methotrexate-associated lymphoproliferative disorders in the central nervous system and stomach: A case report
por: Kawazoe, Mai, et al.
Publicado: (2020)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
por: Okamoto, Michinari, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pd7e1qi50t4l7dokpcjkm0qmhk